LOX, but not LOXL2, promotes bone metastasis formation and bone destruction in triple-negative breast cancer - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Journal of Bone Oncology Année : 2024

LOX, but not LOXL2, promotes bone metastasis formation and bone destruction in triple-negative breast cancer

Résumé

The primary function of the lysyl oxidase (LOX) family, including LOX and its paralogue LOX-like (LOXL)-2, is to catalyze the covalent crosslinking of collagen and elastin in the extracellular matrix. LOX and LOXL2 are also facilitating breast cancer invasion and metastatic spread to visceral organs (lungs, liver) in vivo. Conversely, the contribution of LOX and LOXL2 to breast cancer bone metastasis remains scant. Here, using gene overexpression or silencing strategies, we investigated the role of LOX and LOXL2 on the formation of metastatic osteolytic lesions in animal models of triple negative breast cancer. In vivo, the extent of radiographic metastatic osteolytic lesions in animals injected with LOX-overexpressing [LOX(+)] tumor cells was 3-fold higher than that observed in animals bearing tumors silenced for LOX [LOX(-)]. By contrast, the extent of osteolytic lesions between LOXL2(+) and LOXL2(-) tumor-bearing animals did not differ, and was comparable to that observed with LOX(-) tumor-bearing animals. In situ, TRAP staining of bone tissue sections from the hind limbs of LOX(+) tumor-bearing animals was substantially increased compared to LOX(-), LOXL2(+) and LOXL2(-)-tumor-bearing animals, which was indicative of enhanced active-osteoclast resorption. In vitro, tumor-secreted LOX increased osteoclast differentiation induced by RANKL, whereas LOXL2 seemed to counteract LOX's pro-osteoclastic activity. Furthermore, LOX (but not LOXL2) overexpression in tumor cells induced a robust production of IL-6, the latter being a pro-osteoclastic cytokine. Based on these findings, we propose a model in which LOX and IL-6 secreted from tumor cells act in concert to enhance osteoclast-mediated bone resorption that, in turn, promotes metastatic bone destruction in vivo.
Fichier principal
Vignette du fichier
1-s2.0-S2212137424000022-main.pdf (8.21 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-04426027 , version 1 (31-01-2024)

Identifiants

Citer

Paola Di Mauro, Martine Croset, Lamia Bouazza, Philippe Clézardin, Caroline E Reynaud. LOX, but not LOXL2, promotes bone metastasis formation and bone destruction in triple-negative breast cancer. Journal of Bone Oncology, 2024, 44, pp.100522. ⟨10.1016/j.jbo.2024.100522⟩. ⟨hal-04426027⟩

Collections

UNIV-LYON1 UDL
2 Consultations
5 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More